Regeneron announced that it has entered into a global collaboration agreement with Tessera Therapeutics to commercialize and ...

Eli Lilly has announced a price reduction for Zepbound single-dose vials, targeting improved affordability for self-pay ...

Along with the deployment and integration the new agentic AI tool, FDA is also launching an agentic AI challenge for its ...

New data shows that China and the US dominate breast cancer clinical trial expertise while lower-income countries remain ...

Many PBMs are also finding their business at risk as pharma–PBM tension continues to intensify. We predict that this tension will continue in 2026, especially for companies with late-stage assets in ...

Patient-centric evidence, such as PROs and RWE, offers insights into patients' needs, enhancing drug development beyond traditional endpoints. Challenges include increased complexity and regulatory ...

The agency’s decision is based on claims that the Covid vaccine was linked to the deaths of 10 children.

Eli Lilly reduced Zepbound vial prices for self-paying patients via LillyDirect, aiming to lower obesity treatment costs and ...

How has the rise of GLP-1s impacted businesses outside of pharma? Jay Bregman: Up until, the rise of these medications has ...

In today’s Pharmaceutical Executive Daily, Novo Nordisk files for FDA approval of a higher-dose Wegovy injectable using a ...

Pharmaceutical companies face distinct pricing and market access (P&MA) challenges in Korea and Australia, two of ...

Psychedelics have demonstrated significant progress, generating enthusiasm across the neuroscience industry and leading to successful independent companies. Rare neuromuscular and neurodevelopmental ...